MBRX · All filings · Read this filing
What changed 10-Q
Item 5. Other Information
2022-05-11 compared with 2021-11-10 · 3 added, 2 removed, 24 unchanged (17% of the section changed)
1 unchanged sentence
EXHIBITS 
+Added: Patent and Technology License Agreement dated February 3, 2022, by and between The Board of Regents of The University of Texas System on behalf of The University of Texas M.D.
+Added: Anderson Cancer Center and Moleculin Biotech, Inc.
+Added: (incorporated by reference to Exhibit 10.34 of the Company’s 10-K filed March 24, 2022)
Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
14 unchanged sentences
MOLECULIN BIOTECH, INC.
−Removed: November 10, 2021
/s/ Walter V.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 10, 2021
/s/ Jonathan P.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.